Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $8.00 at HC Wainwright

Sana Biotechnology (NASDAQ:SANA - Get Free Report) had its price objective cut by investment analysts at HC Wainwright from $11.00 to $8.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target points to a potential upside of 135.99% from the stock's previous close.

Several other equities research analysts have also weighed in on SANA. JMP Securities lowered shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research note on Tuesday. Citigroup raised their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, August 9th.

Sana Biotechnology Trading Down 9.8 %

NASDAQ:SANA traded down $0.37 on Tuesday, reaching $3.39. The stock had a trading volume of 3,652,025 shares, compared to its average volume of 2,153,897. The company has a 50-day moving average of $4.42 and a 200 day moving average of $5.90. The stock has a market cap of $754.17 million, a P/E ratio of -2.95 and a beta of 1.44. Sana Biotechnology has a 12-month low of $2.85 and a 12-month high of $12.00.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). On average, equities analysts predict that Sana Biotechnology will post -1.13 EPS for the current year.

Insider Buying and Selling

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of Sana Biotechnology stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the sale, the director now owns 2,848,121 shares of the company's stock, valued at $11,620,333.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 31.10% of the company's stock.

Institutional Investors Weigh In On Sana Biotechnology

Institutional investors have recently modified their holdings of the stock. Blue Trust Inc. raised its holdings in Sana Biotechnology by 1,246.6% in the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company's stock worth $55,000 after acquiring an additional 12,154 shares during the period. Algert Global LLC acquired a new stake in shares of Sana Biotechnology during the 2nd quarter valued at about $73,000. XTX Topco Ltd acquired a new position in Sana Biotechnology in the second quarter valued at about $100,000. Dark Forest Capital Management LP boosted its position in Sana Biotechnology by 112.0% in the second quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company's stock valued at $149,000 after buying an additional 14,430 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Sana Biotechnology by 20.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company's stock worth $163,000 after acquiring an additional 5,090 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.